Seedlabs

Second-Look LAPC: Routing the 'Unresectable' Pancreatic Patient

A second-opinion service that finds expert surgeons for pancreatic cancer patients told their tumor is inoperable.

A second-opinion review service for pancreatic cancer patients told their tumor is inoperable because it wraps around an artery, routing those stable on chemotherapy to the few expert centers where surgery offers a median 20-month survival.

MedicinePancreatic and Hepatic Oncology Research
Metabolism and Genetic DisordersOncology patient navigation and remote second-opinion services

Concept

A records-and-imaging review service for pancreatic cancer patients who have been told their tumor is unresectable because it encases an artery. The patient or their local oncologist uploads CT imaging and treatment history; a reviewing hepatopancreaticobiliary team applies the demonstrated selection pattern — disease controlled on neoadjuvant chemotherapy, fitness for a multivisceral operation — and routes qualifying patients to one of the few centers whose surgeons routinely perform pancreatectomy with arterial dissection (PAD) or arterial resection (PAR). The wedge is deliberately narrow: not choosing between treatments, but correcting the access failure that keeps artery-encased patients away from the small number of surgeons past the 15-case learning curve.

Why now

Paper [0] shows that surgery for artery-encased locally advanced pancreatic cancer — historically a contraindication — delivered a median survival of 20.1 months after surgery and 12.5% five-year survival across 385 patients, that arterial dissection after neoadjuvant chemotherapy is safe (100% of the 190 PAD patients received neoadjuvant therapy), and that in-hospital mortality in the experienced era was 4.8%. The same paper shows PAR is technically demanding with a 15-procedure learning curve, meaning most hospitals cannot offer it — so the demonstrated survival benefit accrues only to patients who reach the right center, which is precisely the gap a routing service closes.

Written by GLM · 14 Oct 2026

AI assessment

Backed by 1 paper92

A highly focused patient-routing service that solves a specific access failure by connecting 'unresectable' pancreatic cancer patients to a tiny subset of surgeons capable of arterial resection.

Evidence strength
5/5
The idea is directly derived from a large-scale study (385 patients) that quantifies both the survival benefit (20.1 months) and the specific barrier (15-case learning curve) that creates the need for this service.
Market pull
4/5
There is high urgency for pancreatic cancer patients and a clear value proposition for high-volume centers seeking qualified surgical candidates.
Novelty & moat
4/5
While other ideas in the catalog focus on decision aids or credentialing, this is a distinct logistics and triage play that addresses the 'access gap' rather than just the 'decision gap'.
Feasibility
5/5
The MVP is a simple secure portal for imaging upload and a review workflow for a small team of expert surgeons, requiring no new medical technology.
Wedge clarity
5/5
The wedge is exceptionally sharp: it focuses exclusively on the 'artery-encased' subset of patients, avoiding the complexity of general oncology triage.
Simplicity / focus
5/5
The product is a single, focused routing service with one clear mechanism and one specific outcome.

Scored by Gemma 4 · 14 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Pancreatic Cancer Action Network (PanCAN)organization

    Runs the largest pancreatic cancer patient navigation program; a validated routing pathway for 'unresectable' arterial cases gives its navigators a concrete referral option backed by 20.1-month median survival rather than 'no surgery'.

  • The University of Texas MD Anderson Cancer Centerorganization

    A high-volume pancreatic surgery program past the learning curve; it receives routed referrals for artery-encased cases it is equipped to operate on after neoadjuvant therapy.

  • National Pancreas Foundationorganization

    A patient-facing pancreatic disease foundation whose mission includes connecting patients to expert care; a second-look review pathway is a direct service to its community.

  • Cleveland Clinicorganization

    Already sells remote second opinions at scale through MyConsult; adding a locally-advanced-pancreatic-cancer arterial review pathway extends an existing telehealth channel with a defined clinical protocol.

Research it builds on

  1. Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve
    M Loos, T Kester, U Klaiber et al. · 2026 · 70 citations
    All ideas from this paper →
Leave feedback
feasibility